| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Optic Neuropathy, Ischemic | 10 | 2022 | 19 | 5.110 |
Why?
|
| Retinal Vessels | 14 | 2018 | 59 | 4.150 |
Why?
|
| Retinal Diseases | 11 | 2023 | 90 | 3.770 |
Why?
|
| Retina | 13 | 2021 | 220 | 3.730 |
Why?
|
| Ischemia | 13 | 2024 | 253 | 3.550 |
Why?
|
| Spinal Fusion | 8 | 2020 | 86 | 3.100 |
Why?
|
| Ischemic Preconditioning | 10 | 2016 | 37 | 2.860 |
Why?
|
| Extracellular Vesicles | 4 | 2023 | 42 | 2.810 |
Why?
|
| Reperfusion Injury | 12 | 2024 | 144 | 2.740 |
Why?
|
| Ischemic Postconditioning | 5 | 2020 | 10 | 2.400 |
Why?
|
| Postoperative Complications | 11 | 2020 | 2314 | 2.170 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2022 | 481 | 1.700 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2017 | 61 | 1.480 |
Why?
|
| Bone Marrow Cells | 3 | 2017 | 262 | 1.430 |
Why?
|
| Rats | 24 | 2023 | 4048 | 1.420 |
Why?
|
| Blindness | 5 | 2022 | 39 | 1.410 |
Why?
|
| Electroretinography | 16 | 2018 | 77 | 1.410 |
Why?
|
| Intraoperative Complications | 4 | 2016 | 185 | 1.270 |
Why?
|
| Culture Media, Conditioned | 3 | 2019 | 103 | 1.250 |
Why?
|
| Retinal Artery Occlusion | 3 | 2018 | 12 | 1.240 |
Why?
|
| Inpatients | 4 | 2020 | 312 | 1.140 |
Why?
|
| Apoptosis | 12 | 2017 | 1718 | 1.040 |
Why?
|
| Hypoxia | 3 | 2023 | 657 | 1.030 |
Why?
|
| Rats, Wistar | 8 | 2020 | 303 | 0.900 |
Why?
|
| Incidence | 9 | 2020 | 1604 | 0.890 |
Why?
|
| Risk Factors | 15 | 2022 | 5562 | 0.890 |
Why?
|
| Neuroprotective Agents | 4 | 2019 | 100 | 0.880 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 2395 | 0.880 |
Why?
|
| Anesthesiology | 2 | 2019 | 157 | 0.870 |
Why?
|
| Morals | 1 | 2024 | 95 | 0.840 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2019 | 1237 | 0.820 |
Why?
|
| Glaucoma | 1 | 2022 | 34 | 0.800 |
Why?
|
| Anesthetics | 1 | 2022 | 53 | 0.800 |
Why?
|
| Spine | 4 | 2009 | 102 | 0.790 |
Why?
|
| Optic Neuritis | 1 | 2021 | 10 | 0.790 |
Why?
|
| Neuromyelitis Optica | 1 | 2021 | 22 | 0.770 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2011 | 125 | 0.770 |
Why?
|
| Animals | 30 | 2024 | 27536 | 0.770 |
Why?
|
| In Situ Nick-End Labeling | 9 | 2017 | 122 | 0.750 |
Why?
|
| Head-Down Tilt | 2 | 2018 | 5 | 0.720 |
Why?
|
| Beclin-1 | 1 | 2020 | 15 | 0.710 |
Why?
|
| Hemodilution | 2 | 2018 | 13 | 0.700 |
Why?
|
| Scoliosis | 1 | 2020 | 32 | 0.700 |
Why?
|
| Retinal Ganglion Cells | 5 | 2024 | 71 | 0.700 |
Why?
|
| Neurosurgical Procedures | 3 | 2010 | 243 | 0.690 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2011 | 341 | 0.680 |
Why?
|
| Research Support as Topic | 1 | 2019 | 85 | 0.650 |
Why?
|
| Eye Diseases | 1 | 2019 | 59 | 0.650 |
Why?
|
| Research Personnel | 1 | 2019 | 72 | 0.650 |
Why?
|
| Ophthalmology | 1 | 2019 | 44 | 0.650 |
Why?
|
| Optic Nerve Injuries | 1 | 2018 | 4 | 0.640 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 125 | 0.640 |
Why?
|
| Neurology | 1 | 2019 | 75 | 0.630 |
Why?
|
| Autophagy | 2 | 2020 | 159 | 0.630 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 163 | 0.620 |
Why?
|
| Hippocampus | 2 | 2021 | 449 | 0.620 |
Why?
|
| Prone Position | 4 | 2009 | 57 | 0.610 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 218 | 0.610 |
Why?
|
| Male | 31 | 2022 | 42690 | 0.600 |
Why?
|
| Learning | 1 | 2021 | 286 | 0.600 |
Why?
|
| Databases, Factual | 7 | 2018 | 866 | 0.590 |
Why?
|
| MicroRNAs | 1 | 2023 | 556 | 0.590 |
Why?
|
| Arthroplasty, Replacement | 1 | 2018 | 37 | 0.580 |
Why?
|
| Retinal Degeneration | 2 | 2017 | 29 | 0.580 |
Why?
|
| Nerve Block | 1 | 2018 | 50 | 0.580 |
Why?
|
| Anesthetics, Local | 1 | 2018 | 77 | 0.570 |
Why?
|
| Glucose | 1 | 2020 | 629 | 0.570 |
Why?
|
| Intraocular Pressure | 6 | 2011 | 57 | 0.570 |
Why?
|
| Eye Proteins | 1 | 2018 | 128 | 0.550 |
Why?
|
| United States | 10 | 2020 | 7114 | 0.530 |
Why?
|
| Anesthesia, Inhalation | 2 | 2015 | 36 | 0.530 |
Why?
|
| Retinal Neurons | 2 | 2021 | 11 | 0.520 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 317 | 0.520 |
Why?
|
| Sex Factors | 5 | 2020 | 1075 | 0.510 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 201 | 0.500 |
Why?
|
| Humans | 37 | 2024 | 89985 | 0.500 |
Why?
|
| Corneal Injuries | 1 | 2015 | 10 | 0.500 |
Why?
|
| Prostatectomy | 3 | 2015 | 476 | 0.500 |
Why?
|
| Blotting, Western | 8 | 2014 | 793 | 0.500 |
Why?
|
| Biomedical Research | 1 | 2019 | 405 | 0.490 |
Why?
|
| Isoflurane | 1 | 2015 | 64 | 0.490 |
Why?
|
| Oxygen | 1 | 2020 | 746 | 0.490 |
Why?
|
| Orthopedic Procedures | 2 | 2009 | 129 | 0.480 |
Why?
|
| Dual Specificity Phosphatase 1 | 2 | 2011 | 17 | 0.460 |
Why?
|
| Heart Diseases | 1 | 2016 | 302 | 0.450 |
Why?
|
| Hysterectomy | 1 | 2015 | 156 | 0.450 |
Why?
|
| Intravitreal Injections | 3 | 2021 | 73 | 0.430 |
Why?
|
| Physicians | 1 | 2019 | 692 | 0.400 |
Why?
|
| Neurons | 5 | 2015 | 1591 | 0.390 |
Why?
|
| Vision Disorders | 2 | 2009 | 75 | 0.390 |
Why?
|
| Middle Aged | 16 | 2020 | 26159 | 0.370 |
Why?
|
| Erythropoietin | 2 | 2009 | 90 | 0.360 |
Why?
|
| Potassium Channels | 3 | 2009 | 346 | 0.360 |
Why?
|
| Anesthesia | 2 | 2010 | 169 | 0.350 |
Why?
|
| Protein Kinase C | 2 | 2008 | 267 | 0.340 |
Why?
|
| Astrocytes | 2 | 2021 | 142 | 0.340 |
Why?
|
| Receptors, Erythropoietin | 2 | 2009 | 14 | 0.340 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 5 | 2010 | 68 | 0.340 |
Why?
|
| Age Factors | 4 | 2020 | 1880 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2009 | 6 | 0.330 |
Why?
|
| Hospital Mortality | 2 | 2010 | 408 | 0.330 |
Why?
|
| Craniotomy | 3 | 2010 | 89 | 0.330 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1983 | 0.330 |
Why?
|
| Surgical Equipment | 1 | 2009 | 4 | 0.330 |
Why?
|
| Aged | 13 | 2018 | 19262 | 0.320 |
Why?
|
| Odds Ratio | 3 | 2018 | 682 | 0.320 |
Why?
|
| Retrospective Studies | 7 | 2022 | 9216 | 0.320 |
Why?
|
| Perioperative Care | 2 | 2022 | 171 | 0.320 |
Why?
|
| Diazoxide | 4 | 2009 | 19 | 0.310 |
Why?
|
| Neurosurgery | 1 | 2010 | 105 | 0.300 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 128 | 0.300 |
Why?
|
| Spinal Cord | 1 | 2009 | 255 | 0.300 |
Why?
|
| Female | 16 | 2020 | 46602 | 0.300 |
Why?
|
| Operating Rooms | 1 | 2009 | 125 | 0.290 |
Why?
|
| Eye Protective Devices | 1 | 2007 | 3 | 0.290 |
Why?
|
| Time Factors | 5 | 2018 | 5358 | 0.270 |
Why?
|
| Risk Assessment | 3 | 2022 | 2327 | 0.250 |
Why?
|
| Tonometry, Ocular | 2 | 2018 | 11 | 0.250 |
Why?
|
| Embolism, Air | 1 | 2004 | 23 | 0.240 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 983 | 0.240 |
Why?
|
| Israel | 1 | 2024 | 57 | 0.230 |
Why?
|
| Phosphorylation | 4 | 2010 | 1130 | 0.230 |
Why?
|
| Comorbidity | 3 | 2016 | 953 | 0.230 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2887 | 0.220 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2024 | 346 | 0.220 |
Why?
|
| Electrodes, Implanted | 1 | 2004 | 185 | 0.220 |
Why?
|
| RNA, Small Interfering | 3 | 2011 | 557 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 226 | 0.210 |
Why?
|
| Eyelids | 2 | 2013 | 23 | 0.200 |
Why?
|
| Child | 4 | 2021 | 7242 | 0.200 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2021 | 9 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 194 | 0.190 |
Why?
|
| Adolescent | 4 | 2020 | 9345 | 0.180 |
Why?
|
| Fluorescence | 1 | 2021 | 103 | 0.180 |
Why?
|
| Staining and Labeling | 1 | 2021 | 169 | 0.180 |
Why?
|
| Logistic Models | 2 | 2018 | 1214 | 0.180 |
Why?
|
| Microglia | 1 | 2021 | 108 | 0.180 |
Why?
|
| Rhabdomyolysis | 1 | 2020 | 28 | 0.170 |
Why?
|
| Registries | 2 | 2019 | 808 | 0.170 |
Why?
|
| Financial Management | 1 | 2019 | 21 | 0.170 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 69 | 0.170 |
Why?
|
| Datasets as Topic | 1 | 2019 | 75 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2023 | 464 | 0.170 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2020 | 160 | 0.170 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 161 | 0.170 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 123 | 0.170 |
Why?
|
| Lysosomes | 1 | 2020 | 113 | 0.160 |
Why?
|
| Robotics | 2 | 2015 | 270 | 0.160 |
Why?
|
| Cell Death | 1 | 2020 | 261 | 0.160 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 66 | 0.160 |
Why?
|
| Cluster Analysis | 1 | 2020 | 371 | 0.160 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 187 | 0.160 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 107 | 0.160 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 6785 | 0.160 |
Why?
|
| RNA Interference | 2 | 2010 | 376 | 0.160 |
Why?
|
| Cytokines | 1 | 2023 | 811 | 0.160 |
Why?
|
| Kinetics | 1 | 2021 | 1534 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2015 | 8277 | 0.150 |
Why?
|
| Perioperative Period | 1 | 2018 | 25 | 0.150 |
Why?
|
| Models, Statistical | 2 | 2020 | 576 | 0.150 |
Why?
|
| Adult | 8 | 2018 | 26827 | 0.150 |
Why?
|
| Cerebral Palsy | 1 | 2018 | 97 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2022 | 1866 | 0.150 |
Why?
|
| Spinal Injuries | 1 | 2017 | 23 | 0.150 |
Why?
|
| Isoenzymes | 2 | 2008 | 274 | 0.150 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2017 | 16 | 0.150 |
Why?
|
| Cell Count | 2 | 2011 | 199 | 0.150 |
Why?
|
| Blood-Retinal Barrier | 1 | 2017 | 4 | 0.140 |
Why?
|
| Biocompatible Materials | 1 | 2019 | 198 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 358 | 0.140 |
Why?
|
| Young Adult | 4 | 2016 | 6415 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2017 | 171 | 0.140 |
Why?
|
| Injections, Intraocular | 1 | 2016 | 5 | 0.140 |
Why?
|
| Capillary Permeability | 1 | 2017 | 132 | 0.130 |
Why?
|
| Obesity | 2 | 2016 | 972 | 0.130 |
Why?
|
| Causality | 1 | 2016 | 80 | 0.130 |
Why?
|
| Facial Muscles | 2 | 2013 | 23 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 241 | 0.130 |
Why?
|
| Anemia | 2 | 2009 | 132 | 0.130 |
Why?
|
| Locomotion | 1 | 2017 | 140 | 0.130 |
Why?
|
| Oculomotor Muscles | 2 | 2013 | 29 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2016 | 171 | 0.130 |
Why?
|
| Spinal Cord Stimulation | 1 | 2015 | 16 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1732 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2009 | 586 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1731 | 0.120 |
Why?
|
| Epilepsy | 1 | 2018 | 424 | 0.110 |
Why?
|
| Cell Line | 1 | 2019 | 2495 | 0.110 |
Why?
|
| Blood Pressure | 2 | 2011 | 906 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2018 | 400 | 0.110 |
Why?
|
| Lumbar Vertebrae | 2 | 2007 | 152 | 0.110 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 104 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2020 | 2886 | 0.110 |
Why?
|
| Tendons | 1 | 2013 | 44 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 644 | 0.110 |
Why?
|
| Chronic Pain | 1 | 2015 | 165 | 0.100 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1670 | 0.100 |
Why?
|
| Reactive Oxygen Species | 2 | 2024 | 490 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 690 | 0.100 |
Why?
|
| Imidazoles | 2 | 2010 | 140 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1452 | 0.100 |
Why?
|
| Leupeptins | 1 | 2011 | 22 | 0.100 |
Why?
|
| Blood Loss, Surgical | 3 | 2009 | 116 | 0.090 |
Why?
|
| Cytoprotection | 1 | 2011 | 47 | 0.090 |
Why?
|
| Retinal Bipolar Cells | 1 | 2010 | 4 | 0.090 |
Why?
|
| Calpain | 1 | 2011 | 113 | 0.090 |
Why?
|
| Solubility | 2 | 2009 | 185 | 0.090 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2010 | 64 | 0.090 |
Why?
|
| Warm Ischemia | 1 | 2010 | 32 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2011 | 278 | 0.090 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 83 | 0.090 |
Why?
|
| Cerebral Revascularization | 1 | 2010 | 28 | 0.090 |
Why?
|
| Blindness, Cortical | 1 | 2009 | 8 | 0.080 |
Why?
|
| Necrosis | 1 | 2010 | 210 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 194 | 0.080 |
Why?
|
| Anisomycin | 1 | 2009 | 9 | 0.080 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2009 | 4 | 0.080 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2009 | 8 | 0.080 |
Why?
|
| Transfusion Reaction | 1 | 2009 | 17 | 0.080 |
Why?
|
| Enzyme Activators | 1 | 2009 | 14 | 0.080 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2009 | 16 | 0.080 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2009 | 13 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 153 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2009 | 94 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2011 | 298 | 0.080 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2009 | 11 | 0.080 |
Why?
|
| Stroke | 1 | 2018 | 994 | 0.080 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2009 | 33 | 0.080 |
Why?
|
| Chlorpropamide | 1 | 2008 | 3 | 0.080 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 73 | 0.080 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2009 | 22 | 0.080 |
Why?
|
| Deep Brain Stimulation | 1 | 2010 | 63 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2009 | 48 | 0.080 |
Why?
|
| Spinal Diseases | 1 | 2009 | 44 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2009 | 281 | 0.080 |
Why?
|
| Benzopyrans | 1 | 2008 | 12 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2009 | 122 | 0.080 |
Why?
|
| Androstadienes | 1 | 2008 | 72 | 0.080 |
Why?
|
| Acetophenones | 1 | 2008 | 27 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2015 | 780 | 0.070 |
Why?
|
| Posture | 2 | 2006 | 125 | 0.070 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 145 | 0.070 |
Why?
|
| Pyridines | 1 | 2009 | 300 | 0.070 |
Why?
|
| Caspases | 2 | 2010 | 155 | 0.070 |
Why?
|
| Head Protective Devices | 1 | 2007 | 20 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 2010 | 784 | 0.070 |
Why?
|
| Eye | 2 | 2005 | 111 | 0.070 |
Why?
|
| Supine Position | 2 | 2006 | 30 | 0.070 |
Why?
|
| Hydroxy Acids | 1 | 2006 | 9 | 0.070 |
Why?
|
| Nitroarginine | 1 | 2006 | 16 | 0.070 |
Why?
|
| Decanoic Acids | 1 | 2006 | 11 | 0.070 |
Why?
|
| Liver Failure, Acute | 1 | 2006 | 39 | 0.070 |
Why?
|
| Length of Stay | 1 | 2010 | 749 | 0.070 |
Why?
|
| Potassium Channel Blockers | 1 | 2006 | 64 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 89 | 0.060 |
Why?
|
| Prevalence | 1 | 2009 | 1250 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 808 | 0.060 |
Why?
|
| Subthalamus | 1 | 2004 | 2 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2006 | 280 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1929 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2005 | 198 | 0.060 |
Why?
|
| Biomarkers | 1 | 2011 | 1778 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 47 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2005 | 193 | 0.060 |
Why?
|
| Reperfusion | 1 | 2024 | 32 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2004 | 109 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 70 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 77 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1747 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 112 | 0.050 |
Why?
|
| Prosthesis Implantation | 1 | 2004 | 129 | 0.050 |
Why?
|
| Caspase 2 | 1 | 2002 | 9 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2004 | 151 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2002 | 46 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 51 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 269 | 0.050 |
Why?
|
| Mitochondria | 1 | 2006 | 556 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2002 | 162 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 98 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 183 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2002 | 201 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1801 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 665 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2009 | 3404 | 0.040 |
Why?
|
| Inflammation | 1 | 2024 | 981 | 0.040 |
Why?
|
| Survivors | 1 | 2018 | 234 | 0.030 |
Why?
|
| Workers' Compensation | 1 | 2015 | 4 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2015 | 17 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2015 | 332 | 0.030 |
Why?
|
| Blepharoptosis | 1 | 2013 | 11 | 0.030 |
Why?
|
| Fasciotomy | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cadaver | 1 | 2013 | 186 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 604 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2497 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 776 | 0.020 |
Why?
|
| Connective Tissue | 1 | 2011 | 23 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1862 | 0.020 |
Why?
|
| Ligaments | 1 | 2011 | 33 | 0.020 |
Why?
|
| Orbit | 1 | 2011 | 39 | 0.020 |
Why?
|
| Smoking | 1 | 2015 | 625 | 0.020 |
Why?
|
| Blood Volume | 1 | 2009 | 49 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 11858 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2009 | 91 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2009 | 46 | 0.020 |
Why?
|
| Medicine | 1 | 2009 | 91 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2009 | 117 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2009 | 102 | 0.020 |
Why?
|
| Indoles | 1 | 2010 | 301 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 422 | 0.020 |
Why?
|
| Skull | 1 | 2009 | 256 | 0.020 |
Why?
|
| Seizures | 1 | 2009 | 307 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 296 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2009 | 738 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2003 | 50 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 258 | 0.010 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2003 | 47 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 115 | 0.010 |
Why?
|
| Liver | 1 | 2006 | 1211 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2769 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 2026 | 0.010 |
Why?
|